Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Exons

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    57 result(s) found for: Exons. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2008-005438-57 Sponsor Protocol Number: HGWH0008 Start Date*: 2008-11-19
    Sponsor Name:Academic Medical Centre
    Full Title: Predictive value of drug elimination gene polymorphisms on clearance and dose adjustment of sunitinib (Sutent, SU11248) in patients with cancer
    Medical condition: The main group are patients with renal cell cancer currently being or about to be treated with sunitinib. Other diseases with efficacy of sunitinib are Gastro Intestinal Stromal cell tumour (GIST).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002069-52 Sponsor Protocol Number: 4045-301 Start Date*: 2017-01-23
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: A Double-Blind, Placebo-Controlled, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
    Medical condition: Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) SE (Completed) DE (Completed) FR (Ongoing) ES (Trial now transitioned) CZ (Trial now transitioned) NL (Ongoing) IT (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned) DK (Trial now transitioned) GR (Completed) NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022951-49 Sponsor Protocol Number: 20100007 Start Date*: 2011-06-06
    Sponsor Name:Amgen Inc
    Full Title: A Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects With Chemorefracto...
    Medical condition: Chemorefractory, Wild-type Kirsten rat sarcoma viral oncogene homolog (KRAS), Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) EE (Completed) LV (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2021-006574-23 Sponsor Protocol Number: AR101-PREVEnt Start Date*: 2022-08-30
    Sponsor Name:Aytu BioPharma, Inc.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled study of enzastaurin for the prevention of arterial events in patients with vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 ...
    Medical condition: vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014316 Ehlers-Danlos syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Ongoing) BE (Prematurely Ended) FR (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002069-30 Sponsor Protocol Number: 13069 Start Date*: 2008-12-05
    Sponsor Name:Bayer Vital GmbH
    Full Title: A randomized, double-blind, single centre, placebo-controlled pilot study to assess on a molecular level the influence of a 5 % dexpanthenol ointment in subjects with previously injured skin by inv...
    Medical condition: Biopsy wounds on healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002393-12 Sponsor Protocol Number: PRODIGE49 Start Date*: 2016-08-26
    Sponsor Name:Fédération Francophone de Cancérologie Digestive
    Full Title: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 and targeted therapy in first-line treatment of metastatic colorectal cancer restricted to the liver
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003407-15 Sponsor Protocol Number: SRP-9001-104 Start Date*: 2023-08-08
    Sponsor Name:Sarepta Therapeutics, Inc
    Full Title: An Open-Label, Systemic Gene Delivery Study to Evaluate the Safety, Tolerability and Expression of SRP-9001 in association with imlifidase in Subjects with Duchenne Muscular Dystrophy with pre-exis...
    Medical condition: Duchenne muscular dystrophy
    Disease:
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2022-000691-19 Sponsor Protocol Number: BN43881 Start Date*: 2022-10-26
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A two-part, open-label systemic gene delivery study to evaluate the safety and expression of RO7494222 (SRP-9001) in subjects under the age of four with Duchenne muscular dystrophy
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10052655 Duchenne muscular dystrophy gene carrier PT
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001053-18 Sponsor Protocol Number: IC 2007-04 Start Date*: 2008-05-29
    Sponsor Name:INSTITUT CURIE
    Full Title: Étude de phase II randomisée évaluant une irradiation pelvienne associée au Cisplatine seul ou au Cisplatine plus Cetuximab chez des patientes présentant un carcinome du col utérin de stade IB2, II...
    Medical condition: Patientes présentant un cancer du col de l’utérus de type épidermoïde ou adénocarcinome de stade Ib2 à IIIb, non antérieurement traitées.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001238-41 Sponsor Protocol Number: 2006-001238-41 Start Date*: 2007-01-04
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: Phase II trial of Erlotinib in combination with increasing dose of gemcitabine given as fixed dose rate infusion in advanced pancreatic cancer.
    Medical condition: Patients with unresectable advanced or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033609 PT
    Population Age: Children, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005595-28 Sponsor Protocol Number: AIO-TRK-0214 Start Date*: 2015-09-29
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Induction therapy with gefitinib followed by taxane platinum chemotherapy and intercalated gefitinib in NSCLC stages II-IIIB with activating EGFR mutation – A single arm Phase II trial.
    Medical condition: Patients with stage II, IIIA and IIIB non-squamous non-small-cell lung cancer with activating EGFR mutation
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10073254 Neoadjuvant therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000077-83 Sponsor Protocol Number: SRP-9001-101 Start Date*: 2022-11-10
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: Systemic gene delivery Phase I/IIa clinical trial for Duchenne muscular dystrophy using rAAVrh74.MHCK7.micro-dystrophin (microDys-IV-001)
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10052655 Duchenne muscular dystrophy gene carrier PT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-000078-27 Sponsor Protocol Number: SRP-9001-102 Start Date*: 2022-11-10
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial for Duchenne Muscular Dystrophy Using SRP-9001
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10052655 Duchenne muscular dystrophy gene carrier PT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-002167-23 Sponsor Protocol Number: IPC_2011-001 Start Date*: 2013-06-12
    Sponsor Name:Institut Paoli-Calmettes
    Full Title: A phase Ib/II open-label study evaluating safety and efficacy of oral BKM120 in combination with lapatinib in HER2+/PI3K-activated, trastuzumab-resistant locally advanced, recurrent and metastatic ...
    Medical condition: locally advanced, recurrent and metastatic breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004849-11 Sponsor Protocol Number: AIO-KRK-0116 Start Date*: 2016-09-29
    Sponsor Name:University Clinic od Munich-Großhadern (represented by the medical management)
    Full Title: Randomised study to investigate FOLFOXIRI plus cetuximab or FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutated metastatic colorectal cancer (FIRE-4.5)
    Medical condition: Histologically confirmed, UICC stage IV adenocarcinoma of the colon or rectum with metastases (metastatic colorectal cancer, mCRC), primarily non-resectable or surgery refused by the patient; RAS ...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004223-20 Sponsor Protocol Number: FIRE-8 Start Date*: 2021-06-15
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatme...
    Medical condition: Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatme...
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004403-31 Sponsor Protocol Number: MITOEND-3 Start Date*: 2022-03-24
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: MITO END-3: A randomized phase II trial of Carboplatin+Paclitaxel compared to Carboplatin+Paclitaxel+Avelumab in advanced (stage III-IV) or recurrent endometrial cancer
    Medical condition: advanced (stage III-IV) or recurrent endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10007342 Carcinoma endometrial LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003374-91 Sponsor Protocol Number: SRP-9001-301 Start Date*: 2022-09-12
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBA...
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10052655 Duchenne muscular dystrophy gene carrier PT
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: FR (Completed) BE (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001762-42 Sponsor Protocol Number: 4658-402 Start Date*: 2020-04-03
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of a High Dose of Eteplirsen, Preceded by an Open-Label Dose Escalation, in Patients with Duchenne Muscular ...
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: IE (Completed) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing) SE (Prematurely Ended) DE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) NO (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) SI (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000951-29 Sponsor Protocol Number: 4658-102 Start Date*: 2017-06-22
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: An Open-Label Safety, Tolerability, and Pharmacokinetics Study of Eteplirsen in Young Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
    Medical condition: Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 13:21:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA